131 related articles for article (PubMed ID: 38546761)
1. Trends of pre-treatment drug resistance in antiretroviral-naïve people with HIV-1 in the era of second-generation integrase strand-transfer inhibitors in Taiwan.
Chen GJ; Cheng CY; Yang CJ; Lee NY; Tang HJ; Huang SH; Huang MH; Liou BH; Lee YC; Lin CY; Hung TC; Lin SP; Sun HY; Chang SY; Hung CC;
J Antimicrob Chemother; 2024 May; 79(5):1157-1163. PubMed ID: 38546761
[TBL] [Abstract][Full Text] [Related]
2. Applying Next-Generation Sequencing to Track HIV-1 Drug Resistance Mutations Circulating in Portugal.
Pimentel V; Pingarilho M; Sebastião CS; Miranda M; Gonçalves F; Cabanas J; Costa I; Diogo I; Fernandes S; Costa O; Corte-Real R; Martins MRO; Seabra SG; Abecasis AB; Gomes P
Viruses; 2024 Apr; 16(4):. PubMed ID: 38675962
[TBL] [Abstract][Full Text] [Related]
3. Transmitted Drug Resistance to Integrase-Based First-Line Human Immunodeficiency Virus Antiretroviral Regimens in Mediterranean Europe.
de Salazar A; Viñuela L; Fuentes A; Teyssou E; Charpentier C; Lambert-Niclot S; Serrano-Conde E; Pingarilho M; Fabeni L; De Monte A; Stefic K; Perno CF; Aguilera A; Falces I; Delgado R; Fernandes S; Diogo I; Gomes P; Paraskevis D; Santoro MM; Ceccherini-Silberstein F; Marcelin AG; Garcia F
Clin Infect Dis; 2023 May; 76(9):1628-1635. PubMed ID: 36571282
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of pretreatment HIV resistance to integrase inhibitors in West African and Southeast Asian countries.
Aghokeng AF; Ngo-Giang-Huong N; Huynh THK; Dagnra AY; D'Aquin Toni T; Maiga AI; Dramane K; Eymard-Duvernay S; Chaix ML; Calvez V; Descamps D;
J Antimicrob Chemother; 2024 May; 79(5):1164-1168. PubMed ID: 38546752
[TBL] [Abstract][Full Text] [Related]
5. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
6. Trends in HIV-1 pretreatment drug resistance and HIV-1 variant dynamics among antiretroviral therapy-naive Ethiopians from 2003 to 2018: a pooled sequence analysis.
Kiros M; Biset S; Gebremariam B; Yalew GT; Abegaz WE; Geteneh A
Virol J; 2023 Oct; 20(1):243. PubMed ID: 37880705
[TBL] [Abstract][Full Text] [Related]
7. Genetic diversity and antiretroviral resistance-associated mutation profile of treated and naive HIV-1 infected patients from the Northwest and Southwest regions of Cameroon.
Meriki HD; Tufon KA; Anong DN; Atanga PN; Anyangwe IA; Cho-Ngwa F; Nkuo-Akenji T
PLoS One; 2019; 14(11):e0225575. PubMed ID: 31751428
[TBL] [Abstract][Full Text] [Related]
8. High predictive efficacy of integrase strand transfer inhibitors in perinatally HIV-1-infected African children in therapeutic failure of first- and second-line antiretroviral drug regimens recommended by the WHO.
Mboumba Bouassa RS; Mossoro-Kpinde CD; Gody JC; Veyer D; Péré H; Matta M; Robin L; Grésenguet G; Charpentier C; Bélec L
J Antimicrob Chemother; 2019 Jul; 74(7):2030-2038. PubMed ID: 30891603
[TBL] [Abstract][Full Text] [Related]
9. Integrase Strand Transfer Inhibitors (INSTIs) Resistance Mutations in HIV-1 Infected Turkish Patients.
Sayan M; Gündüz A; Ersöz G; İnan A; Deveci A; Özgür G; Sargın F; Karagöz G; İnci A; İnan D; Ülçay A; Karaoğlan I; Kaya S; Kutlu SS; Süer K; Çağatay A; Akalın H
HIV Clin Trials; 2016 May; 17(3):109-13. PubMed ID: 27125365
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of Integrase Strand Transfer Inhibitors (INSTI) Resistance Mutations in Taiwan.
Chang SY; Lin PH; Cheng CL; Chen MY; Sun HY; Hsieh SM; Sheng WH; Su YC; Su LH; Chang SF; Liu WC; Hung CC; Chang SC
Sci Rep; 2016 Oct; 6():35779. PubMed ID: 27779200
[TBL] [Abstract][Full Text] [Related]
11. Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada.
Bourgi K; Jenkins CA; Rebeiro PF; Palella F; Moore RD; Altoff KN; Gill J; Rabkin CS; Gange SJ; Horberg MA; Margolick J; Li J; Wong C; Willig A; Lima VD; Crane H; Thorne J; Silverberg M; Kirk G; Mathews WC; Sterling TR; Lake J; Koethe JR;
J Int AIDS Soc; 2020 Apr; 23(4):e25484. PubMed ID: 32294337
[TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy and safety of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: a systematic review and network meta-analysis.
Snedecor SJ; Radford M; Kratochvil D; Grove R; Punekar YS
BMC Infect Dis; 2019 May; 19(1):484. PubMed ID: 31146698
[TBL] [Abstract][Full Text] [Related]
13. Treatment outcomes of integrase inhibitors, boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors in antiretroviral-naïve persons starting treatment.
Mocroft A; Neesgard B; Zangerle R; Rieger A; Castagna A; Spagnuolo V; Antinori A; Lampe FC; Youle M; Vehreschild JJ; Mussini C; Borghi V; Begovac J; Duvivier C; Gunthard HF; Rauch A; Tiraboschi J; Chkhartishvili N; Bolokadze N; Wit F; Wasmuth JC; De Wit S; Necsoi C; Pradier C; Svedhem V; Stephan C; Petoumenos K; Garges H; Rogatto F; Peters L; Ryom L;
HIV Med; 2020 Oct; 21(9):599-606. PubMed ID: 32588958
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of drug resistance mutations among ART-naive and -experienced HIV-infected patients in Sierra Leone.
Yendewa GA; Sahr F; Lakoh S; Ruiz M; Patiño L; Tabernilla A; Deen GF; Sesay M; Salata RA; Poveda E
J Antimicrob Chemother; 2019 Jul; 74(7):2024-2029. PubMed ID: 30989237
[TBL] [Abstract][Full Text] [Related]
15. HIV pretreatment drug resistance among cisgender MSM and transgender women from Lima, Peru.
Trebelcock WL; Lama JR; Duerr A; Sanchez H; Cabello R; Gilada T; Segura P; Reisner SL; Mayer KH; Mullins J; Bender Ignacio RA
J Int AIDS Soc; 2019 Nov; 22(11):e25411. PubMed ID: 31773888
[TBL] [Abstract][Full Text] [Related]
16. Trends in HIV-1 Drug Resistance Mutations from a U.S. Reference Laboratory from 2006 to 2017.
Kagan RM; Dunn KJ; Snell GP; Nettles RE; Kaufman HW
AIDS Res Hum Retroviruses; 2019 Aug; 35(8):698-709. PubMed ID: 31169022
[TBL] [Abstract][Full Text] [Related]
17. Primary resistance to integrase strand-transfer inhibitors in Europe.
Casadellà M; van Ham PM; Noguera-Julian M; van Kessel A; Pou C; Hofstra LM; Santos JR; Garcia F; Struck D; Alexiev I; Bakken Kran AM; Hoepelman AI; Kostrikis LG; Somogyi S; Liitsola K; Linka M; Nielsen C; Otelea D; Paraskevis D; Poljak M; Puchhammer-Stöckl E; Staneková D; Stanojevic M; Van Laethem K; Zidovec Lepej S; Clotet B; Boucher CA; Paredes R; Wensing AM;
J Antimicrob Chemother; 2015 Oct; 70(10):2885-8. PubMed ID: 26188038
[TBL] [Abstract][Full Text] [Related]
18. Absence of Integrase Strand Transfer Inhibitor Associated Resistance in Antiretroviral Therapy Naïve and Experienced Individuals from Western India.
Karade S; Sen S; Sashindran VK
AIDS Res Hum Retroviruses; 2019 Jun; 35(6):567-571. PubMed ID: 30793915
[TBL] [Abstract][Full Text] [Related]
19. Low Frequency of Integrase Inhibitor Resistance Mutations Among Therapy-Naïve HIV Patients in Southeast China.
Lai J; Liu Y; Han X; Huang A; Lin J; Ao W; Ye H; Chen Y
Drug Des Devel Ther; 2021; 15():889-894. PubMed ID: 33679129
[TBL] [Abstract][Full Text] [Related]
20. Cardiometabolic Differences in People Living with HIV Receiving Integrase Strand Transfer Inhibitors Compared to Non-nucleoside Reverse Transcriptase Inhibitors: Implications for Current ART Strategies.
Vos WAJW; Vadaq N; Matzaraki V; Otten T; Groenendijk AL; Blaauw MJT; van Eekeren LE; Brinkman K; de Mast Q; Riksen NP; Stalenhoef AFH; van Lunzen J; van der Ven AJAM; Blok WL; Stalenhoef JE
Viruses; 2024 Apr; 16(4):. PubMed ID: 38675924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
